XFOR Ebit from 2010 to 2024
XFOR Stock | USD 1.01 0.03 3.06% |
EBIT | First Reported 2016-12-31 | Previous Quarter -25.2 M | Current Value -37.3 M | Quarterly Volatility 7.7 M |
Check X4 Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XFOR main balance sheet or income statement drivers, such as Interest Income of 3.5 M, Depreciation And Amortization of 3.6 M or Interest Expense of 3 M, as well as many exotic indicators such as Price To Sales Ratio of 40.66, Dividend Yield of 0.0 or PTB Ratio of 3.06. XFOR financial statements analysis is a perfect complement when working with X4 Pharmaceuticals Valuation or Volatility modules.
XFOR | Ebit |
Latest X4 Pharmaceuticals' Ebit Growth Pattern
Below is the plot of the Ebit of X4 Pharmaceuticals over the last few years. It is X4 Pharmaceuticals' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in X4 Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Ebit | 10 Years Trend |
|
Ebit |
Timeline |
XFOR Ebit Regression Statistics
Arithmetic Mean | (44,433,260) | |
Coefficient Of Variation | (80.26) | |
Mean Deviation | 30,309,512 | |
Median | (32,262,000) | |
Standard Deviation | 35,662,530 | |
Sample Variance | 1271.8T | |
Range | 94.8M | |
R-Value | (0.94) | |
Mean Square Error | 161.1T | |
R-Squared | 0.88 | |
Slope | (7,490,769) | |
Total Sum of Squares | 17805.4T |
XFOR Ebit History
Other Fundumenentals of X4 Pharmaceuticals
About X4 Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include X4 Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. X4 Pharmaceuticals investors use historical funamental indicators, such as X4 Pharmaceuticals's Ebit, to determine how well the company is positioned to perform in the future. Although X4 Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in X4 Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on X4 Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on X4 Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in X4 Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
EBIT | -107.5 M | -102.1 M | |
EBITDA | -105.5 M | -100.2 M | |
Ebt Per Ebit | 0.94 | 0.78 | |
Ebit Per Revenue | (22.95) | (24.10) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of X4 Pharmaceuticals Correlation against competitors. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for XFOR Stock analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.67) | Return On Assets (0.61) | Return On Equity (4.89) |
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.